Breakthrough
Brandon Walsh, 2019 — on SuperRare
Owned byslfsvrgn.eth
Description
In 2019, the FDA assigned psilocybin "breakthrough therapy" status for the treatment of depression.
On-chain
Market
Provenance
In 2019, the FDA assigned psilocybin "breakthrough therapy" status for the treatment of depression.
